{"id":"NCT02540954","sponsor":"Bayer","briefTitle":"Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","officialTitle":"An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-29","primaryCompletion":"2019-12-24","completion":"2020-06-04","firstPosted":"2015-09-04","resultsPosted":"2021-04-08","lastUpdate":"2021-06-11"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","otherNames":[]}],"arms":[{"label":"Aflibercept extended dosing","type":"EXPERIMENTAL"},{"label":"Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)","primaryOutcome":{"measure":"Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye","timeFrame":"From baseline to Week 52","effectByArm":[{"arm":"Aflibercept Extended Dosing","deltaMin":-0.3,"sd":7.5},{"arm":"Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)","deltaMin":-0.5,"sd":8.4}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"51 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":71,"countries":["Austria","Canada","Czechia","France","Germany","Hungary","Italy","Lithuania","Poland","Portugal","Slovakia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["38183525"],"seeAlso":["http://clinicaltrials.bayer.com/","http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":167},"commonTop":["Cataract","Subretinal fluid","Visual acuity reduced","Choroidal neovascularisation","Neovascular age-related macular degeneration"]}}